<DOC>
	<DOCNO>NCT00002725</DOCNO>
	<brief_summary>Phase II trial study effectiveness bryostatin-1 treating patient recurrent non-Hodgkin 's lymphoma . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Bryostatin-1 Treating Patients With Recurrent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response bryostatin 1 ( BRYO ) administer weekly 3 week patient relapse non-Hodgkin 's lymphoma . II . Assess toxic effect treatment . III . Establish correlation PKC isoenzyme activity BRYO function lymphoma cell normal lymphocyte . IV . Determine pharmacokinetic profile BRYO relationship pharmacodynamics . OUTLINE : Single-Agent Chemotherapy/Differentiation Therapy . Bryostatin 1 , BRYO , NSC-339555 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma Working formulation low , intermediate , highgrade histology eligible Mantle cell marginal zone lymphoma eligible Relapse least 1 doxorubicincontaining regimen require No 2 prior chemotherapy regimens One prior biologic therapy addition 2 prior chemotherapy regimen allow No prior bone marrow transplantation Ineligible treatment high priority protocols Patients eligible bone marrow transplantation may treat reduce tumor bulk Bidimensionally measurable disease require No history primary metastatic CNS disease PATIENT CHARACTERISTICS : Age : Any age Performance status : Zubrod 02 Life expectancy : Greater 12 week Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Bilirubin great 1.8 mg/dL Transaminases great 2.5 time normal Creatinine great 1.5 mg/dL OR creatinine clearance great 70 mL/min No HIV antibody No serious intercurrent illness No pregnant nursing woman Effective contraception require fertile patient throughout study 1 year thereafter PRIOR CONCURRENT THERAPY : At least 4 week since prior therapy ( 6 week since mitomycin ) recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2000</verification_date>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>